NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

Key Takeaways

• CMS Medicare now covers NeoGenomics' PanTracer LBx liquid biopsy
• Test analyzes over 500 genes, including MSI and bTMB
• Seven‑day turnaround enables rapid, actionable treatment decisions
• Can be ordered standalone, reflex, or alongside tissue testing
• Expands precision oncology access for Medicare patients in community settings

Summary

NeoGenomics announced that its PanTracer™ LBx liquid biopsy test has received Medicare coverage under CMS’s MolDX program. The CLIA‑certified assay profiles more than 500 genes, including MSI and blood‑tumor mutational burden, with a seven‑day turnaround. Coverage allows Medicare beneficiaries to obtain the non‑invasive test as a standalone, reflex, or concurrent option with tissue profiling, facilitating therapy selection and trial enrollment for advanced solid tumors. The decision bolsters NeoGenomics’ precision‑oncology portfolio and may accelerate broader clinical adoption.

Pulse Analysis

The recent CMS MolDX decision marks a pivotal moment for the liquid biopsy sector, where reimbursement has long lagged behind technological advances. By adding PanTracer™ LBx to the Medicare formulary, regulators signal confidence in non‑invasive genomic profiling as a standard of care for solid tumors. This move aligns with broader payer trends that prioritize value‑based diagnostics, potentially encouraging other insurers to follow suit and expanding the test’s reach beyond fee‑for‑service environments.

PanTracer LBx distinguishes itself with a comprehensive panel covering more than 500 cancer‑related genes, including microsatellite instability (MSI) and blood‑tumor mutational burden (bTMB). The seven‑day turnaround time shortens the diagnostic interval, enabling oncologists to match patients with targeted therapies or clinical trials sooner. Its flexibility—available as a standalone order, a reflex test when tissue samples are insufficient, or in parallel with tissue sequencing—addresses real‑world workflow challenges and supports longitudinal disease monitoring across community and academic settings.

From a business perspective, Medicare coverage could drive significant volume growth for NeoGenomics, reinforcing its position against competitors such as Guardant Health and Foundation Medicine. The added reimbursement pathway may also attract partnership opportunities with pharmaceutical firms seeking reliable companion diagnostics for emerging therapies. Investors will likely view the coverage as a catalyst for revenue acceleration, while the broader oncology market may see faster adoption of liquid biopsy as a routine component of precision medicine strategies.